Get the tools used by (smart)2 investors.

EV / EBITDA for Axsome Therapeutics Inc

Join now and get access to the full platform

Search for company or ETF

 

  0 results available. Select is focused ,type to refine list, press Down to open the menu,

AXSM: Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercia...

106.27 USD
Price
USD
Fair Value
Upside
64.11 - 139.13
52-week range

Analysis

Fiscal Years
Trailing Twelve Months
Fiscal Halfs
Fiscal Quarters
Daily
Hide this widget

The following section summarizes insights on Axsome Therapeutics Inc's EV / EBITDA:

Dec 2016Dec 2018Dec 2020Dec 2022Dec 2024-80.0x-60.0x-40.0x-20.0x

Performance Summary
  • Axsome Therapeutics's latest twelve months ev / ebitda is -20.7x
  • Axsome Therapeutics's ev / ebitda for fiscal years ending December 2020 to 2024 averaged -21.5x.
  • Axsome Therapeutics's operated at median ev / ebitda of -20.7x from fiscal years ending December 2020 to 2024.
  • Looking back at the last 5 years, Axsome Therapeutics's ev / ebitda peaked in December 2021 at -11.4x.
  • Axsome Therapeutics's ev / ebitda hit its 5-year low in December 2020 of -33.7x.
  • Axsome Therapeutics's ev / ebitda decreased in 2022 (-21.3x, +88.0%) and 2024 (-20.7x, +2.8%) and increased in 2020 (-33.7x, -53.5%), 2021 (-11.4x, -66.3%), and 2023 (-20.1x, -5.7%).

How does Axsome Therapeutics Inc's EV / EBITDA benchmark against competitors?

Hide this widget

We've identified the following companies as similar to Axsome Therapeutics Inc because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.

Metric Usage: EV / EBITDA

Hide this widget
ev_to_ebitda_ltm
Slug
number
Datatype
text
Format
current
Default Period
FY, LTM
Periods Supported
Free
Plan

To view the full list of supported financial metrics please see Complete Metrics Listing.

Similar Metrics

Hide this widget

Metrics similar to EV / EBITDA in the valuation category include:

  • Price / Tangible Book Value - Compares a firm's market value of equity to its book value of tangible common equity value.
  • Price Close (Unadjusted) - The price at the close of the trading day that have not been adjusted for splits and cash dividends.
  • Market Cap / LTM Revenue - Indicates the multiple of revenue that stock investors are willing to pay for one share of the firm.
  • WACC - Our estimate of the weighted average cost of capital for a company.
View Full List

Search for metric or datapoint

EV / EBITDA

Measures the dollars in Enterprise Value for each dollar of EBITDA over the last twelve months.

Definition of EV / EBITDA

Hide this widget

LTM EBITDA Multiple is defined as:

EBITDA Multiple = Enterprise Value / LTM EBITDA

Applying this formula, Axsome Therapeutics’s EV/EBITDA Ratio is calculated below:

Enterprise Value [ $5.06 B ]
(/) EBITDA [ -$244.5 M ]
(=) EV/EBITDA Ratio [ −20.7x ]

The tables below summarizes the trend in Axsome Therapeutics’s EV/EBITDA Ratio over the last five years:

Date Enterprise Value EBITDA EV/EBITDA Ratio
2020-12-31 $2.888 B -$85.603 M −33.7
2021-12-31 $1.359 B -$119.7 M −11.4
2022-12-31 $3.216 B -$150.6 M −21.3
2023-12-31 $3.535 B -$175.7 M −20.1
2024-12-31 $5.06 B -$244.5 M −20.7

EBITDA Multiple, Enterprise Value / EBITDA, or EV / EBITDA measures the dollars in Enterprise Value for each dollar of EBITDA.

EBITDA is used in the denominator since it is capital structure neutral and can be used to compare companies with different levels of debt (See EBITDA for benefits). We use Enterprise Value as the numerator to consider the claims on EBITDA of both debt and equity holders.

Strong revenue and EBITDA growth are highly correlated with higher EBITDA Multiples.

Read more about enterprise value (ev) and ebitda


Click the link below to download a spreadsheet with an example EV / EBITDA calculation for Axsome Therapeutics Inc below:

Sector Benchmark Analysis

Sector
Industry Group
Industry
Hide this widget
-66.7x-31.7x3.3x64.0x100300500

The chart above depicts the distribution of ev / ebitda for companies operating in the Healthcare sector in the Developed economic region. Over 2,180 companies were considered in this analysis, and 2,100 had meaningful values. The average ev / ebitda of companies in the sector is 1.3x with a standard deviation of 13.9x.

Axsome Therapeutics Inc's EV / EBITDA of -20.7x ranks in the 4.8% percentile for the sector. The following table provides additional summary stats:

EV / EBITDA In The Healthcare Sector
Economic Risk RegionDeveloped
Total Constituents2,188
Included Constituents2,100
Min-65.0x
Max62.9x
Median-0.3x
Mean1.3x
Standard Deviation13.9x

You can find companies with similar ev / ebitda using this stock screener.

All rights reserved. Terms Of Use